Nuclear β-catenin immunoexpression in scars

J Cutan Pathol. 2021 Jan;48(1):18-23. doi: 10.1111/cup.13806. Epub 2020 Aug 6.

Abstract

Background: Histopathologically, scars can mimic superficial fibromatoses. Superficial fibromatoses are known to show nuclear β-catenin immunoexpression, although the tumor types do not harbor CTNNB1 or APC alterations. This study aimed to evaluate nuclear β-catenin immunoexpression in scars compared to that in superficial fibromatoses.

Methods: Immunostaining with an anti-β-catenin antibody, clone 14, was performed on 8 superficial fibromatoses and 22 scars. The extent of β-catenin nuclear staining was classified as negative (<10%), focally positive (10-49%), or diffusely positive (50-100%). β-catenin staining intensity was semi-quantitatively graded as weak, moderate, or strong.

Results: In 21 (95%) scars, nuclear β-catenin immunoexpression was detected in fibroblasts/myofibroblasts, with mainly diffuse (16/21) and moderate (14/21) to strong (5/21) staining. In contrast, seven (88%) of the eight superficial fibromatoses expressed β-catenin in the nuclei of the lesional spindle cells, at varying levels of staining intensity. Fibroblasts in normal papillary dermis always showed nuclear β-catenin expression to varying degrees but those in the reticular dermis did not.

Conclusions: Scars typically exhibit nuclear β-catenin expression similar to that in superficial fibromatoses. Thus, β-catenin immunohistochemistry is not suitable for distinguishing superficial fibromatoses from scars.

Keywords: hypertrophic scar; keloid; scar; superficial fibromatosis; β-catenin.

MeSH terms

  • Biomarkers / analysis*
  • Cell Nucleus / metabolism
  • Cicatrix / diagnosis*
  • Cicatrix / metabolism
  • Cicatrix / pathology*
  • Diagnosis, Differential
  • Fibroma / diagnosis
  • Fibroma / metabolism
  • Fibroma / pathology
  • Humans
  • Immunohistochemistry
  • beta Catenin / biosynthesis*

Substances

  • Biomarkers
  • CTNNB1 protein, human
  • beta Catenin